An Effective, High Throughput Impedance-based Assay to Evaluate Potency of Immunotherapy Products
In this webinar, Dr. Juan Miguel Sanchez Nieto from Catapult Cell and Gene Therapy describes a simple workflow to evaluate the potency of T-cell receptor (TCR) and Chimeric Antigen Receptor (CAR-T) based therapies for solid and non-solid tumours.
Watch the webinar on demand to learn:
- Challenges associated with current methodologies to evaluate cell therapy potency
- How the xCELLigence platform overcomes these limitations by accurately measuring potency in real time
- How to develop and qualify the xCELLigence assay to measure T-cell cytotoxicity using suspension or adherent target cell lines
Advances in genetic engineering have improved specificity, safety and potency of T-cell receptor (TCR) and Chimeric Antigen Receptor (CAR-T) based therapies for solid and non-solid tumours. These developments have allowed the manufacturing and commercialisation of these immunotherapy ATPMs (advanced therapy medicinal products). However, there is a current need to develop more robust product release assays to shorten product release time, including methods to ensure the identity, safety or potency of the product. Current methodologies to evaluate product potency require cell labelling, are labour intensive and only provide information about product’s specific cytotoxic effect at one selected time-point. The xCELLigence platform overcomes these limitations by measuring electrical impedance over time. In this presentation we will discuss how to develop and qualify the use of a high-throughput impedance-based system to measure T-cell cytotoxicity for both TCR or CAR-T approaches using either suspension or adherent target cell lines.
About the Speaker
Juan Miguel Sánchez Nieto studied Biotechnology at Francisco de Vitoria University (Madrid, Spain). He moved to London in 2010 where he did an MSc in Molecular Medicine at UCL. Juan Miguel continued his scientific career at Imperial College London, where he completed a PhD in Developmental and Stem Cell Biology. His research was focused on understanding the differential sensitivity to cell death observed at the onset of embryonic stem cell differentiation. He joined Catapult Cell and Gene Therapy´s Industrialisation team in 2017 as an Analytical Development Scientist. Juan Miguel has been involved in the experimental design and execution of multiple projects related to the development of novel analytics for viral vector, stem cell and somatic cell therapies. Juan Miguel has been leading Catapult Cell and Gene Therapy's efforts in the development and qualification of in vitro potency assays for TCR and CAR-T cell-based immunotherapies.